Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Int J Hyperthermia. 2021;38(1):1627-1632. doi: 10.1080/02656736.2021.2001582.
To compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC). To evaluate the impact of thermal dose in hyperthermia treatment.
We analyzed data retrieved from the medical records of patients with intermediate-/high-risk NMIBC treated with intravesical mitomycin (IM group) or locoregional deep hyperthermia combined with intravesical mitomycin (CHT group) at a single tertiary care hospital between May 2016 and June 2019. The primary and secondary endpoints were the recurrence-free survival rate and progression-free survival rate, respectively. Thermal dose was evaluated and adverse events were also recorded.
In total, 43 patients (CHT: 18 patients, IM: 25 patients) were enrolled. The median follow-up durations were 14 and 23 months, respectively. The recurrence rate at 12 months was significantly lower in the CHT group than in the IM group (11.1% vs. 44%, = .048); this trend persisted at 24 months (CHT: 11.1%, IM: 48%; = .027). The recurrence-free survival was also significantly higher in the CHT group than in the IM group ( = .028). No tumor recurrence was noted in patients who received a thermal dose of ≥4 CEM43. All adverse events were well tolerated, and there was no treatment-related mortality.
Intravesical chemotherapy combined with locoregional deep hyperthermia for intermediate-/high-risk papillary NMIBC can significantly decrease the recurrence rate relative to that observed after intravesical chemotherapy alone.
比较局部深部热疗联合膀胱内化疗与单纯膀胱内化疗治疗中高危非肌层浸润性膀胱癌（NMIBC）的疗效。评估热疗中热剂量的影响。
我们分析了 2016 年 5 月至 2019 年 6 月期间在一家三级保健医院接受膀胱内丝裂霉素（IM 组）或局部深部热疗联合膀胱内丝裂霉素（CHT 组）治疗的中高危 NMIBC 患者的病历数据。主要终点和次要终点分别为无复发生存率和无进展生存率。评估了热剂量并记录了不良反应。
共纳入 43 例患者（CHT：18 例，IM：25 例）。中位随访时间分别为 14 个月和 23 个月。12 个月时 CHT 组的复发率明显低于 IM 组（11.1% vs. 44%， = .048）；24 个月时仍有此趋势（CHT：11.1%，IM：48%； = .027）。CHT 组的无复发生存率也明显高于 IM 组（ = .028）。接受热剂量≥4 CEM43 的患者均未出现肿瘤复发。所有不良反应均耐受良好，无治疗相关死亡。
对于中高危乳头状 NMIBC，膀胱内化疗联合局部深部热疗可显著降低复发率，优于单纯膀胱内化疗。
